Skip to content


    DEA Class; Rx

    Common Brand Names; Velban

    • Antineoplastics, Vinca Alkaloid

    Vinblastine is a member of the Vinca alkaloid antineoplastic agents; extracted from the periwinkle plant; similar to vincristine in action and structure, but the alkaloids significantly differ in toxicities and spectrum of activity; the dose-limiting toxicity of vinblastine is bone-marrow suppression.

    Indicated for the treatment of breast cancer.

    For the treatment of Langerhans’ cell histiocytosis.
    For the treatment of Hodgkin lymphoma.
    For the treatment of non-Hodgkin’s lymphoma (NHL).
    For the treatment of testicular cancer or choriocarcinoma.
    For the treatment of cutaneous T-cell lymphoma (CTCL) (aka mycosis fungoides).
    For the treatment of Kaposi’s sarcoma.
    For the treatment of bladder cancer.


    Intrathecal (IT) administration

    Active bacterial infection


    • Anemia
    • Leukopenia
    • Myelosuppression
    • Alopecia
    • Peripheral neuropathy
    • Hypertension
    • Bronchospasm
    • Nausea
    • Vomiting
    • Anorexia
    • Diarrhea
    • Constipation
    • Paralytic ileus
    • Jaw pain
    • Aspermia
    • Amenorrhea

    Bone marrow depression, neuropathy, neuromuscular disease may occur

    Caution when administering neurotoxic agents, ototoxic agents concomitantly

    Caution in pulmonary disease, liver impairment, intestinal obstruction, paralytic ileus

    Potential for jaw/parotid pain, hoarseness & dysphagia due to cranial neuropathy


    Previous radiation treatment or chemotherapy

    Avoid pregnancy

    Pregnancy Category: D

    Lactation: not known if excreted in breast milk, do not nurse


    18.5 mg/m2 IV administered in weekly intervals.


    18.5 mg/m2 IV administered in weekly intervals.


    12.5 mg/m2/day IV administered weekly.


    12.5 mg/m2/day IV administered weekly.

    Vinblastine sulfate

    injectable solution

    • 1mg/mL

    powder for injection

    • 10mg